Centriolar satellites assemble centrosomal microcephaly proteins to recruit CDK2 and promote centriole duplication

  1. Andrew Kodani
  2. Timothy W Yu
  3. Jeffrey R Johnson
  4. Divya Jayaraman
  5. Tasha L Johnson
  6. Lihadh Al-Gazali
  7. Lāszló Sztriha
  8. Jennifer N Partlow
  9. Hanjun Kim
  10. Alexis L Krup
  11. Alexander Dammermann
  12. Nevan Krogan
  13. Christopher A Walsh
  14. Jeremy F Reiter  Is a corresponding author
  1. University of California, San Francisco, United States
  2. Howard Hughes Medical Institute, Boston Children's Hospital, United States
  3. United Arab Emirates University, United Arab Emirates
  4. Howard Hughes Medical Institute, Boston Children's Hospital, Boston, United States

Abstract

Primary microcephaly (MCPH) associated proteins CDK5RAP2, CEP152, WDR62 and CEP63 colocalize at the centrosome. We found that they interact to promote centriole duplication and form a hierarchy in which each is required to localize another to the centrosome, with CDK5RAP2 at the apex, and CEP152, WDR62 and CEP63 at sequentially lower positions. MCPH proteins interact with distinct centriolar satellite proteins; CDK5RAP2 interacts with SPAG5 and CEP72, CEP152 with CEP131, WDR62 with MOONRAKER, and CEP63 with CEP90 and CCDC14. These satellite proteins localize their cognate MCPH interactors to centrosomes and also promote centriole duplication. Consistent with a role for satellites in microcephaly, homozygous mutations in one satellite gene,CEP90, may cause MCPH. The satellite proteins, with the exception of CCDC14, and MCPH proteins promote centriole duplication by recruiting CDK2 to the centrosome. Thus, centriolar satellites build a MCPH complex critical for human neurodevelopment that promotes CDK2 centrosomal localization and centriole duplication.

Article and author information

Author details

  1. Andrew Kodani

    Department of Biochemistry and Biophysics, Cardiovascular Research Institute, University of California, San Francisco, San Francisco, United States
    Competing interests
    The authors declare that no competing interests exist.
  2. Timothy W Yu

    Howard Hughes Medical Institute, Boston Children's Hospital, Boston, United States
    Competing interests
    The authors declare that no competing interests exist.
  3. Jeffrey R Johnson

    Department of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, United States
    Competing interests
    The authors declare that no competing interests exist.
  4. Divya Jayaraman

    Howard Hughes Medical Institute, Boston Children's Hospital, Boston, United States
    Competing interests
    The authors declare that no competing interests exist.
  5. Tasha L Johnson

    Department of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, United States
    Competing interests
    The authors declare that no competing interests exist.
  6. Lihadh Al-Gazali

    Department of Paediatrics, College of Medicine and Health Sciences, United Arab Emirates University, Al-Ain, United Arab Emirates
    Competing interests
    The authors declare that no competing interests exist.
  7. Lāszló Sztriha

    Department of Paediatrics, College of Medicine and Health Sciences, United Arab Emirates University, Al-Ain, United Arab Emirates
    Competing interests
    The authors declare that no competing interests exist.
  8. Jennifer N Partlow

    Howard Hughes Medical Institute, Boston Children's Hospital, Boston, United States
    Competing interests
    The authors declare that no competing interests exist.
  9. Hanjun Kim

    Department of Biochemistry and Biophysics, Cardiovascular Research Institute, University of California, San Francisco, San Francisco, United States
    Competing interests
    The authors declare that no competing interests exist.
  10. Alexis L Krup

    Department of Biochemistry and Biophysics, Cardiovascular Research Institute, University of California, San Francisco, San Francisco, United States
    Competing interests
    The authors declare that no competing interests exist.
  11. Alexander Dammermann

    Department of Paediatrics, College of Medicine and Health Sciences, United Arab Emirates University, Al-Ain, United Arab Emirates
    Competing interests
    The authors declare that no competing interests exist.
  12. Nevan Krogan

    Department of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, United States
    Competing interests
    The authors declare that no competing interests exist.
  13. Christopher A Walsh

    Howard Hughes Medical Institute, Boston Children's Hospital, Boston, Boston, United States
    Competing interests
    The authors declare that no competing interests exist.
  14. Jeremy F Reiter

    Department of Biochemistry and Biophysics, Cardiovascular Research Institute, University of California, San Francisco, San Francisco, United States
    For correspondence
    Jeremy.Reiter@ucsf.edu
    Competing interests
    The authors declare that no competing interests exist.

Reviewing Editor

  1. W James Nelson, Stanford University, United States

Ethics

Human subjects: Subjects were identified and evaluated in a clinical setting for medical history, cognitive impairment and physical abnormalities. Peripheral blood samples were collected from the affected individuals and family members after obtaining written informed consent according to the protocols approved by the participating institutions and the ethical standards of the responsible national and institutional committees on human subject research.

Version history

  1. Received: March 18, 2015
  2. Accepted: August 21, 2015
  3. Accepted Manuscript published: August 22, 2015 (version 1)
  4. Accepted Manuscript updated: August 24, 2015 (version 2)
  5. Accepted Manuscript updated: September 2, 2015 (version 3)
  6. Version of Record published: September 18, 2015 (version 4)

Copyright

© 2015, Kodani et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 4,001
    views
  • 1,258
    downloads
  • 112
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Andrew Kodani
  2. Timothy W Yu
  3. Jeffrey R Johnson
  4. Divya Jayaraman
  5. Tasha L Johnson
  6. Lihadh Al-Gazali
  7. Lāszló Sztriha
  8. Jennifer N Partlow
  9. Hanjun Kim
  10. Alexis L Krup
  11. Alexander Dammermann
  12. Nevan Krogan
  13. Christopher A Walsh
  14. Jeremy F Reiter
(2015)
Centriolar satellites assemble centrosomal microcephaly proteins to recruit CDK2 and promote centriole duplication
eLife 4:e07519.
https://doi.org/10.7554/eLife.07519

Share this article

https://doi.org/10.7554/eLife.07519

Further reading

    1. Cell Biology
    Jun Yang, Shitian Zou ... Xiaochun Bai
    Research Article

    Quiescence (G0) maintenance and exit are crucial for tissue homeostasis and regeneration in mammals. Here, we show that methyl-CpG binding protein 2 (Mecp2) expression is cell cycle-dependent and negatively regulates quiescence exit in cultured cells and in an injury-induced liver regeneration mouse model. Specifically, acute reduction of Mecp2 is required for efficient quiescence exit as deletion of Mecp2 accelerates, while overexpression of Mecp2 delays quiescence exit, and forced expression of Mecp2 after Mecp2 conditional knockout rescues cell cycle reentry. The E3 ligase Nedd4 mediates the ubiquitination and degradation of Mecp2, and thus facilitates quiescence exit. A genome-wide study uncovered the dual role of Mecp2 in preventing quiescence exit by transcriptionally activating metabolic genes while repressing proliferation-associated genes. Particularly disruption of two nuclear receptors, Rara or Nr1h3, accelerates quiescence exit, mimicking the Mecp2 depletion phenotype. Our studies unravel a previously unrecognized role for Mecp2 as an essential regulator of quiescence exit and tissue regeneration.

    1. Cancer Biology
    2. Cell Biology
    Stefanie Schmieder
    Insight

    Mutations in the gene for β-catenin cause liver cancer cells to release fewer exosomes, which reduces the number of immune cells infiltrating the tumor.